Literature DB >> 9585811

Mechanisms of recovery from experimental autoimmune encephalomyelitis: T cell deletion and immune deviation in myelin basic protein T cell receptor transgenic mice.

Y Chen1, W W Hancock, R Marks, P Gonnella, H L Weiner.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a Th1-type cell-mediated autoimmune disease directed against central nervous system (CNS) myelin antigens such as myelin basic protein (MBP). EaE is usually characterized by spontaneous remission of clinical disease and immune pathology despite the persistence of self myelin antigens in the central nervous system. Following induction of an acute episode of EAE, spontaneous remission also occurs in MBP T cell receptor (TCR) transgenic mice even through most T cells express a TCT specific for MBP. To investigate the mechanisms of recovery associated with EAE, we examined the behavior of MBP-specific T cells in the MBP TCR transgenic mouse model during disease progression and recovery. We found that recovery from EAE was associated with three major immunologic changes: (1) deletion of encephalitogenic T cells in the brain; (2) deviation of MBP-specific transgenic (Tg+) T cells both in the periphery and in the central nervous system from INF- gamma secretin Th1 type cells to cells that secrete IL-4, IL-10, and TGF- beta ; and (3) deletion of Tg+ T cells in the thymus through apoptosis. Thus spontaneous recovery from a classic Th1 type organ specific autoimmune disease is associated with two mechanisms of immune tolerance, deletion of autoreactive cells and immune deviation of autoreactive cells to a non-pathogenic phenotype.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9585811     DOI: 10.1016/s0165-5728(97)00193-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

Review 1.  Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.

Authors:  H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis.

Authors:  G C Suvannavejh; M C Dal Canto; L A Matis; S D Miller
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

3.  Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis.

Authors:  S Issazadeh; K Abdallah; T Chitnis; A Chandraker; A D Wells; L A Turka; M H Sayegh; S J Khoury
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

4.  Hyperactivation of nuclear factor of activated T cells 1 (NFAT1) in T cells attenuates severity of murine autoimmune encephalomyelitis.

Authors:  Srimoyee Ghosh; Sergei B Koralov; Irena Stevanovic; Mark S Sundrud; Yoshiteru Sasaki; Klaus Rajewsky; Anjana Rao; Martin R Müller
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-09       Impact factor: 11.205

5.  Anamnestic recall of stroke-related deficits: an animal model.

Authors:  Dannielle Zierath; Jessica Hadwin; Anna Savos; Kelly T Carter; Allison Kunze; Kyra J Becker
Journal:  Stroke       Date:  2010-10-14       Impact factor: 7.914

6.  Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.

Authors:  M Comabella; K Balashov; S Issazadeh; D Smith; H L Weiner; S J Khoury
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

7.  A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC.

Authors:  J Lori Blanchfield; Mark D Mannie
Journal:  J Leukoc Biol       Date:  2010-03       Impact factor: 4.962

Review 8.  Oral tolerance.

Authors:  Henry Yim Wu; Howard L Weiner
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

9.  Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.

Authors:  Francesco Patti; Salvatore Lo Fermo
Journal:  Autoimmune Dis       Date:  2011-03-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.